Celltrion Healthcare Australia and Juno Pharmaceuticals Australia Partner on Biosimilars

SYDNEY, AUSTRALIA – Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab). Celltrion Healthcare Australia, a division of the biosimilar developer Celltrion Healthcare, are the Marketing Authorisation holders in Australia for these and other biosimilar brands and will distribute the products in the market. Juno as a leading supplier into hospitals, has been appointed to provide sales promotion and hospital contracting services to Australian Hospital market customers.

Commenting on this partnership, Cecilia Sung – Country Manager ANZ stated that Celltrion Healthcare Australia is pleased with the opportunity to partner with Juno Pharmaceuticals to offer our global biosimilar brands to Australian Healthcare professionals and patients, with a blend of quality & economic benefits. We are also confident that with an extensive commercial network, strong customer relationships and established hospital market presence by Juno Pharmaceuticals, Biosimilar brands from Celltrion Healthcare will achieve high customer acceptance as they have been in regulated markets such as EU/ USA.    

“We are excited that Celltrion has chosen Juno to represent their rituximab and trastuzumab products in Australia. The Juno team has very extensive experience with biosimilars in the Australian marketplace over the last decade” says Mark Crotty, CEO Juno Australia.

Juno Pharmaceuticals Acquires Noradrenaline 2 mg/2 mL & 4 mg/4 mL from Mayne Pharma

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce the acquisition of noradrenaline 2 mg/2 mL and 4 mg/4 mL concentrated injection from Mayne Pharma; an important addition to Juno’s growing range of vasopressors and critical care medicines.

As part of the acquisition, Juno will receive the intellectual property and regulatory approvals for NORADRENALINE MYX 2 mg/2 mL concentrated solution for injection ampoule and NORADRENALINE MYX 4 mg/4 mL concentrated solution for injection ampoule, along with associated contracts and agreements.

This acquisition is Juno’s second for 2019 and is another milestone in Juno’s continued growth and vision to be the leader in supply of off-patent products in hospitals across Australia and New Zealand.

Our focus on hospital injectable medicines and hospital customers makes us ideally placed to supply this product in the Australian market, noted Juno CEO & Managing Director, Mark Crotty. It is exciting to see our range of hospital products growing rapidly, customers see us as their trusted partner in this area.

The agreement comes into effect on July 16^th, 2019 and Juno’s Key Account Managers will work closely with customers and wholesalers to ensure a smooth transition and continuity of supply. As with all Juno products, continuous, reliable supply is a top priority.

From July 16^th, 2019, all commercial enquiries regarding noradrenaline should be directed to your local Juno representative.  Any adverse event reporting, product complaints and medical enquiries should directed to Juno Medical Information on 1800 620 076 or medical-enquiries@junopharm.com.au

• Noradrenaline product information available here.
• Noradrenaline consumer medicine information available here.

About Juno

Juno Pharmaceuticals is a rapidly growing, local Australian and New Zealand business and are experts in off-patent prescription pharmaceuticals. Juno’s portfolio includes medicines across a diverse range of therapeutic areas, with hospital products the core focus of the business. The acquisition of this portfolio is in line with Juno’s mission to improve the health of society, through delivering high quality products to patients, and value to hospitals, the government and tax payers.

Med263. Prepared July 2019.

Juno Acquires Local Portfolio of Essential Injectable Medicines from AstraZeneca

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals Pty Ltd is pleased to announce the acquisition of a local portfolio of essential injectable medicines from AstraZeneca Pty Ltd.  This acquisition will see Juno’s product range grow to over 60 molecules, focussed mainly in the hospital segment.

As part of the acquisition, Juno will receive the intellectual property and regulatory approvals for ten products (eight unique molecules), along with associated contracts and agreements.

This acquisition is the second Juno has made since commencing sales in 2015 and is another milestone in Juno’s continued growth and vision to be the leader in supply of off-patent products in hospitals across Australia and New Zealand.

These critical medicines play a vital role in patient care in Australian and New Zealand hospitals. Our focus at Juno is to build a compelling portfolio that meets the local and unique needs of Australian and New Zealand hospitals, noted Juno CEO & Managing Director, Mark Crotty.

The agreement comes into effect on April 1^st, 2019 and Juno’s key account managers will work closely with customers and wholesalers to ensure a smooth transition.

From April 1^st, 2019, all commercial enquiries regarding the products below should be directed to your local Juno representative.  Any adverse event reporting, product complaints and medical enquiries should directed to Juno Medical Information on 1800 620 076 or medical-enquiries@junopharm.com.au

• ASTRAZENECA SODIUM CHLORIDE 20% 2g/10mL injection BP ampoule
• ASTRAZENECA POTASSIUM CHLORIDE 750mg/10mL injection ampoule
• ASTRAZENECA ATROPINE SULFATE 600 microgram/1mL injection BP ampoule
• ASTRAZENECA ATROPINE SULFATE 1.2mg/1mL injection BP ampoule
• ASTRAZENECA SUXAMETHONIUM CHLORIDE 100mg/2mL injection BP ampoule
• ASTRAZENECA NEOSTIGMINE METHYLSULFATE 0.5mg/1mL injection BP ampoule
• ASTRAZENECA NEOSTIGMINE METHYLSULFATE 2.5mg/1mL injection BP ampoule
• ASTRAZENECA PANCURONIUM BROMIDE 4mg/2mL injection BP ampoule
• ASTRAZENECA PETHIDINE HYDROCHLORIDE 100mg/2mL injection BP ampoule
• ASTRAZENECA FENTANYL 100 microgram/2mL (as citrate) injection ampoule
• ASTRAZENECA FENTANYL 500 microgram/10mL (as citrate) injection ampoule

(more…)

Juno Pharmaceuticals $30,000 Emerging Researcher Grant

Juno’s support of the Society of Hospital Pharmacists of Australia (SHPA) has today been strengthened, with the announcement of a new $30,000 research grant. The provision of this grant will provide up and coming Australian clinical pharmacists with an unprecedented opportunity to improve patient safety in the use of high-risk medicines.
The new research grant is yet another way in which Juno is seeking to collaborate with hospitals, hospital pharmacists and the professional organisation (SHPA) that represents them.
CEO and Managing Director of Juno, Mark Crotty, had this to say –
“Juno is looking forward to strengthening its support of SHPA through the $30,000 Emerging Researcher Grant. As an organisation, Juno embraces and encourages innovation and continuous improvement. Therefore, we are excited about the opportunity this provides to pharmacists and potential this research has to improve patient outcomes.”
CEO of SHPA, Kristin Michaels, says “SHPA and Juno are proud to join forces to support emerging researchers in their quest to improve the safe use of high-risk medicines.”
Perfect for emerging pharmacy researchers with previous proven experience, the Emerging Researcher Grant provides a “next step” towards supporting future, larger research projects while funding initiatives that directly improve patient safety in current practice.
The new grant, available through SHPA’s National Translational Research Collaborative (NTRC) has almost doubled their pool of funding available to date. Evaluation of research projects will be an independent process, conducted by the NTRC Research Grants Committee.
For more information on the grant, including application criteria, key dates and a link to submit expressions of interest, visit www.shpa.org.au/juno-grant

About SHPA
The Society of Hospital Pharmacists of Australia (SHPA) is the national, professional, for-purpose organisation for leading pharmacists and pharmacy technicians working across Australia’s health system, advocating for their pivotal role improving the safety and quality of medicines use. Embedded in multidisciplinary medical teams and equipped with exceptional medicines management expertise, SHPA members are progressive advocates for clinical excellence, committed to evidence-based practice and passionate about patient care. For more information on SHPA, visit www.shpa.org.au/

About The NTRC
The NTRC is a virtual hub connecting Australia’s brightest clinical pharmacy researchers to build capacity and inter-hospital partnerships, strengthen proposals and impact, and leverage funding opportunities. The NTRC helps turn more pharmacists into pharmacy researchers, an advancement that furthers the workforce as a whole, ensuring the development and introduction of new and improved clinical services. For more information on the NTRC, www.shpa.org.au/ntrc

Med202. Prepared July 2018.

Amneal Portfolio Acquisition

Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers.

“Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno assets and Juno is particularly excited to be managing products such as Bicnu (carmustine)” says CEO and Managing Director, Mark Crotty.

Juno is a rapidly growing local Australian business which recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering, including with international and local generic suppliers and innovative discovery companies, and has a focus on local Australian hospital customer needs. The acquisition of select Amneal products is Juno’s first since its formation in 2013. When added to the existing portfolio and strong pipeline, the acquisition positions Juno as one of the largest generic injectable product hospital suppliers in the Australian market.

The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.

For all queries please contact:

Mark Crotty, +61424 152 881